Scott Rocklage, Ph.D. is a renowned scientist based in Boston who is a Managing Partner at 5AM Ventures since 2004. Before then, he worked at the firm as a venture partner. Dr. Rocklage got his degree in Chemistry from the University of California. He also holds a Ph.D. in Chemistry obtained from the Massachusetts Institute of Technology. While at MIT, he conducted his research work in, 2005 Nobel Prize winner in Chemistry, Richard Schrock’s laboratory.
Dr. Rocklage has over 30 years of experience in healthcare management coupled with several years of leadership roles that led the Food and Drug Administration to approve three U.S. New Drug Applications namely Teslascan, Omniscan, and Cubicin. He has also presented several drug candidates in clinical tests.
Dr. Rocklage explains that 5AM Ventures is a life-science-based venture capital firm and 5AM represents the early stage nature of the company formation business. His days at the company are always busy since he has many roles which include assisting management teams and attending board meetings. When he is not working, he spends time reading in new areas of science. He works with other scientists and businesspeople to help them develop drugs by shaping their ideas into real production and testing. He is excited about the use of genotypes and specific mutations to treat cancer in new innovative ways.
On entrepreneurship, Dr. Rocklage insists that a business should focus more on the people it hires when starting. Hiring the wrong people can slow down the growth of your company. He also encourages to take control of the future of their businesses by being risk-takers.
Dr. Rocklage has more than a hundred peer-reviewed publications to his name and is also a holder of over 30 US patents. He also adds up as the Chairman of the Board of Directors at Rennovia, Kinestral, and Cidara (https://www.bloomberg.com/research/stocks/private/person.asp?personId=216045&privcapId=3200727). Dr. Rocklage has also served as the CEO and Chairman of Cubist Pharmaceuticals as well as the CEO and President of Nycomed Salutar. Previously, he served as the Chairman of Relypsa’s Board of Directors. Besides, he also sits on the boards of Epirus and Pulmatrix.